LLL. A. Levchenko

L. A. Levchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


L. A. Levchenko has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modern approaches to the management of children with Alagille syndrome

    by L. A. Levchenko, K. S. Zizyukina, T. Yu. Kravchenko, T. Lungu, A. A. Petrichenko, А. A. Gryaznova, A. Ya. Ilyina, H. A. Sarkisyan

    Alagille syndrome is a disease with a predominantly autosomal dominant type of inheritance, characterized by multisystem damage caused by mutations in the JAG1 and NOTCH2 genes. The most common manifestations of this syndrome are intrahepatic cholestasis due to underdevelopment of the bile ducts, heart defects, maxillofacial dysmorphism, vertebral pathology — radiographically manifested as “butterfly vertebrae”, ophthalmological disorders, vascular anomalies and kidney pathology. In addition to the above, a violation of neuropsychic and physical development is significant. The use of high-tech diagnostic methods in the observation of such children allows us to identify rare disorders that require equally close monitoring by doctors of a multidisciplinary team. The presented article is devoted to modern approaches to the management of children with Alagille syndrome, emphasizing variability of clinical manifestations, diagnostic features and new targeted drugs for the treatment of patients with this disease.

  • Surfactant and surfactant therapy in neonates: from the beginning to the modern features of the application

    by K. S. Zizyukina, H. A. Sarkisyan, L. D. Vorona, L. A. Levchenko, E. I. Shabelnikova, A. P. Khokhlova, Sh. T. Abasova, P. V. Shumilov, Е. А. Саркисян

    Surfactant is a secreted surface-active substance that provides the first breath of the newborn by reducing the surface tension of the alveoli. Surfactant preparations were the first and most popular drugs in neonatology, saving the lives of millions of premature babies. Successful treatment with surfactants is preceded by an individual personalized approach to each child and early detection of newborns with surfactant deficiency. Determining the indications for surfactant therapy, choosing an effective method of drug delivery, selecting concomitant respiratory support are current areas of neonatology to this day. The article reflects the history of use, new approaches to surfactant therapy and methods of administration of various surfactant preparations.


  • Apert syndrome: modern aspects of diagnosis and treatment

    by S. S. Kantutis, E. A. Sarkisyan, P. V. Shumilov, L. D. Vorona, O. V. Pravoslavnaya, L. A. Levchenko, E. I. Shabelnikova, M. A. Sokolova, A. I. Krapivkin

    The purpose of this review is to raise awareness of medical professionals about the features of the clinical picture, the possibilities of diagnosis (including prenatal) and therapy of patients with Apert syndrome to further improve the prognosis and improve the quality of life. Acrocephalosyndactyly is a group of rare congenital syndromes characterized by the presence of acrocephaly, craniofacial anomalies, syndactyly of the hands and feet. According to the literature, the most common form of аcrocephalosyndactyly is Apert syndrome (acrocephalosyndactyly type I, Apert syndrome, ICD 10 Q 87.0, OMIM 101200). This is a genetic disease inherited by an autosomal dominant type. CA is caused by a mutation of the fibroblast growth factor receptor type 2 gene (FGFR2) located on the long arm of chromosome 10, which leads to increased bone metabolism and impaired bone synthesis. The frequency of Apert syndrome is about 15 cases per 1,000,000 live births. Wheaton first reported this pathology in 1894, and in 1906 the French pediatrician Eugene Apert published a series of nine clinical cases with a characteristic triad of symptoms. Apert syndrome is characterized by craniosynostosis, bilateral symmetrical limb syndactyly and dysmorphic facial features. Hypoplasia of the upper jaw and bicoronal synostosis are two noticeable craniofacial defects that lead to a flat, deepened appearance of the forehead and the middle part of the face. Hypertelorism and excessive orbitality, low-set ears, flat nose and cleft palate are often found. Cardiovascular, neurological and genitourinary abnormalities may be present. Diagnosis is based on clinical criteria and molecular genetic testing. There is a possibility of prenatal detection of Apert syndrome.


  • Crouzon syndrome: features of clinical manifestations, management and outcomes in children

    by M. A. Sokolova, E. A. Sarkisyan, P. V. Shumilov, L. D. Vorona, L. A. Levchenko, Yu. L. Ishutina, E. I. Shabelnikova, A. I. Krapivkin

    Syndromic craniosynostosis is a special group of hereditary pathologies. One of the syndromic craniosynostoses is Crouzon syndrome, an autosomal dominant pathology of the primary violation of the fusion of cranial sutures. It occurs with a frequency of 1:60,000 newborns. The disease leads to a number of secondary complications, such as exophthalmos, orthognathic problems, impaired vision, hearing, breathing, lag in neuropsychic development. The development of Crouzon syndrome is associated with a missense mutation in the fibroblast growth factor receptor-2 (FGFR2) gene. In modern medicine, a variant of Crouzon syndrome with black acanthosis is also known, the development of which is associated with a mutation in the FGFR3 gene. The similarity of clinical manifestations as with others syndromic craniosynostoses, also between 2 variants of Crouzon syndrome, leads to difficulties in differential diagnostic search. Knowledge and awareness of the full clinical presentation of this syndrome makes it possible to timely diagnose and treat, prevent possible severe complications and improve the quality of life of patients with Crouzon syndrome. This article describes 2 clinical cases with mutations in the FGFR2 and FGFR3 genes.


  • Beckwith–Wiedemann syndrome in the practice of neonatologist and pediatric surgeon

    by D.M. Mushcherova, H.A. Sarkisyan, P.V. Shumilov, L.D. Vorona, Moscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children, A.P. Khokhlova, L.A. Levchenko, S.V. Cherkasova, A.S. Ilyushkina, Yu.L. Ishutina, et al.

    Beckwith–Wiedemann syndrome is the most frequent congenital anomaly (1 in 13,700 live births worldwide) manifested by overgrowth at the early stages of development. The syndrome is characterized by a complex type of inheritance and is due to a number of different genetic causes and epigenetic changes leading to impaired transcription of growth regulatory genes located on the short arm of chromosome 11. The clinical presentation varies widely, but the main diagnostic criteria include macrosomia, macroglossia, anterior abdominal wall defects, visceromegaly, and unusual facial features (hypoplasia of the middle third, hemangioma of the forehead skin, creases in the earlobe). The danger of the pathology lies in possible complications, including neonatal hypoglycemia and a high incidence of fetal tumors, which determines the need for early diagnosis of the syndrome and further long-term follow-up of a child. This article presents a rare clinical case of Beckwith–Wiedemann syndrome in a newborn with persistent hypoglycemia who underwent a unique surgery to correct macroglossia. Key words: macroglossia, macrosomia, neonatal hypoglycemia, omphalocele, Beckwith–Wiedemann syndrome, overgrowth syndromes, partial glossectomy

  • Current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns

    by A.P. Khokhlova, D.M. Mushcherova, H.A. Sarkisyan, L.D. Vorona, Moscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children, L.A. Levchenko, S.V. Cherkasova, A.S. Ilyushkina, E.S. Nifatova, P.V. Shumilov

    Beckwith–Wiedemann syndrome (OMIM 130650, Q87.3) is a congenital anomaly characterized by overgrowth. It has a wide range of clinical manifestations, but the three main features include macrosomia, macroglossia, and anterior abdominal wall defect. The prevalence of the disease is 1 in 13,700 newborns worldwide, equally represented in males and females. Epigenetic and genetic changes on chromosome 11p15.5 are etiological factors: loss of maternal methylation at IC2 (KCNQ1OT1), paternal uniparental disomy, mutation in the CDKN1C gene, maternal hypermethylation at IC1 (H19), cytogenetically visible duplication of chromosome 11p15, and translocation/inversion of chromosome 11p15. Genetic heterogeneity and the possibility of cellular mosaicism in this syndrome cause phenotypic differences between patients, as well as the complexity of molecular genetic confirmation. An important aspect in the management of patients with Beckwith-Wiedemann syndrome is timely detection and correction of hypoglycemia as a predictor of neurological deficit, as well as long-term monitoring for early detection of malignant neoplasms, including Wilms tumor. Treatment is currently symptomatic, including therapeutic and surgical management, but potential approaches to targeted therapy are being explored. Timely diagnosis of the disease improves longterm outcomes and quality of life of children with this pathology. This article presents current approaches to the diagnosis and management of Beckwith–Wiedemann syndrome in newborns. Key words: genomic imprinting disorders, hypoglycemia, anterior abdominal wall defect, macroglossia, macrosomia, Wilms tumor, Beckwith–Wiedemann syndrome

  • Hemorrhagic disease of the newborn: modern approaches to diagnosis, prevention and treatment

    by E.M. Rashkova, A.A. Shakirova, H.A. Sarkisyan, L.A. Levchenko, S.V. Cherkasova, E.I. Shabelnikova

    Background. Hemorrhagic disease of the newborn is a pathological condition in newborns and children during the first months of life, caused by vitamin K deficiency of dependent blood coagulation factors and manifested by increased bleeding. The incidence of hemorrhagic disease of the newborn varies in different regions of the world, in Russia, according to the literature data, it ranges from 0.25 to 1.7%. Hemorrhagic disease of the newborn is characterized by the development of bleeding and hemorrhage, which negatively affect the function and further development of a number of organs and systems of the child, especially the central nervous system and the gastrointestinal tract. Based on the etiology of the development of the disease described above, HDN is classified into primary (idiopathic) and secondary. Depending on the age of onset, early is distinguished – it manifests itself in the first 24 hours of life, classical – develops on the 2-7th day and late, manifesting itself after 1 week of life (rarely occurs at the age of up to 6 months of life, and some authors indicate the age children under 1 year of age) hemorrhagic disease of the newborn forms. The key priority of neonatologists is to single out from the number of born children, newborns who are at risk for HRD for the purpose of prophylactic administration of vitamin K to them, which will prevent severe undesirable consequences of the disease.A genetic study using logistic regression analysis confirmed a higher risk of intraventricular hemorrhages in newborns with polymorphisms in the VKORC1 genes, which is responsible for the binding of vitamin K1 to cysteine, and thus for a decrease in its concentration in carriers of this gene. Despite the variability in approaches to doses, methods and timing of administration, parenteral administration of vitamin K is the only reliable and preferred way to prevent this disease. In the case of the development of hemorrhagic disease of the newborn, modern approaches to the diagnosis and treatment of this pathology have been developed. Results. The article presents modern approaches to the prevention, diagnosis and therapy of vitamin K-dependent hemorrhagic disease of the newborn.


  • Current approaches to respiratory pathology in late preterm infants

    by E. A. Sarkisyan, S. V. Dumova, A. I. Volkova, O. L. Chugunova, I. V. Zhuravleva, L. A. Levchenko, E. I. Shabelnikova, P. V. Shumilov

    Late preterm babies are those born between 340/7 and 366/7 weeks of gestation, constituting the largest subgroup of preterm infants. Despite the relative morphofunctional maturity, these children remain at a high risk of damage to various organs and systems, and there is also a high mortality rate. One of the top places in the structure of morbidity in late preterm is occupied by respiratory disorders. Quite often there is transient tachypnea, respiratory distress syndrome of the newborn, pulmonary hypertension, and congenital pneumonia. Currently, there are various approaches to prevention, treatment, and diagnosis of respiratory disorders in late preterm children. Until now, the issue of the advisability of prenatal prevention of respiratory distress syndrome with corticosteroids after the 34th week of gestation has not been resolved. Non-invasive methods of respiratory support are more popular along with minimally invasive administration of surfactant preparations when indicated. The trend towards an annual increase in late preterm births determines the need to improve the methods of their nursing. The control over respiratory disorders and hypoxia is crucial in the prevention of adverse outcomes in late preterm children.


  • Hereditary tyrosinemia type 1 in an infant with multiple congenital defects

    by H.A. Sarkisyan, S.V. Cherkasova, A.A. Fadeeva, A.S. Yarushnikova, Y.S. Piliuzina, A.B. Smolyannikova, E.I. Shabelnikova, L.M. Makarova, M.A. Ovsyannikova, L.A. Levchenko, et al.

    Hereditary tyrosinemia type 1 or hepatorenal tyrosinemia is a severe orphan autosomal-recessive disorder of tyrosine metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). The disease is diagnosed in approximately 1:100 000-1:120 000 cases of live births, and in certain regions (such as the Chechen Republic in Russian Federation) the estimated frequency of diagnosis can be significantly higher. In hereditary tyrosinemia type 1, blood levels of tyrosine, succinylacetone and other toxic metabolites are increased, which results in the accumulation of the toxic metabolites in target organs causingliver damage with progressive development of liver failure and liver cirrhosis, damage to the renal tubules resulting in Fanconi syndrome and hypophosphatemic rickets, and central nervous system. In some patients, myocardium could be involved in the pathological process, resulting in the development of hypertrophic cardiomyopathy. The disease presents a great challenge for differential diagnosis due to its polyorganic nature and frequent combination with other hereditary disorders. The modern treatment of hereditary tyrosinemia type 1 includes an elimination-based diet and pathogenetic drug therapy. The potential of genetic engineering methods in target therapy of hereditary tyrosinemia type 1 is being actively researched. Within the article if presented a case of early onset hereditary tyrosinemia type 1 in an infant with multiple congenital defects of central nervous system, including Dandy – Walker syndrome, and congenital defects of maxillofacial area, with signs of an immunodeficiency state and a severe generalized recurring infectious process involving poly-resistant mixed flora. The dynamic changes of neurologic signs are provided for the first year of life of the patient receiving the pathogenetic therapy for the main disease. Laboratory findings are provided, showing the dynamic changes in liver function of the patient.

  • Open Access

    Clinical case of Kasabach–Merritt syndrome in the practice of a neonatologist

    by L.A. Levchenko, P.V. Shumilov, H.A. Sarkisyan, V.V. Shishkina, Ya.M. Chuyko, S.E. Markov

    Клинический случай синдрома Казабаха-Мерритт в практике неонатолога